153 related articles for article (PubMed ID: 2944573)
1. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Wander HE; Nagel GA; Blossey HC; Kleeberg U
Cancer; 1986 Nov; 58(9):1985-9. PubMed ID: 2944573
[TBL] [Abstract][Full Text] [Related]
2. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC
Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer.
Nagel GA; Wander HE; Blossey HC
Cancer Res; 1982 Aug; 42(8 Suppl):3442s-3444s. PubMed ID: 6123383
[TBL] [Abstract][Full Text] [Related]
4. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL
Eur J Cancer; 1990; 26(7):824-7. PubMed ID: 2145904
[TBL] [Abstract][Full Text] [Related]
5. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
6. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.
Halpenny O; Bye A; Cranny A; Feely J; Daly PA
Med Oncol Tumor Pharmacother; 1990; 7(4):241-7. PubMed ID: 2149401
[TBL] [Abstract][Full Text] [Related]
7. Intensive short-term chemotherapy in patients with advanced breast cancer.
Wander HE; Nagel GA; Luig H; Emrich D
Klin Wochenschr; 1987 Apr; 65(7):317-23. PubMed ID: 2953934
[TBL] [Abstract][Full Text] [Related]
8. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Grem JL; Falkson G; Love RR; Tormey DC
Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
[TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
10. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
[TBL] [Abstract][Full Text] [Related]
12. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
13. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
[TBL] [Abstract][Full Text] [Related]
14. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer].
Aikawa T; Yayoi E; Takatsuka Y; Maeura Y; Miyauchi K
Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575
[TBL] [Abstract][Full Text] [Related]
15. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
[TBL] [Abstract][Full Text] [Related]
16. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA
Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938
[No Abstract] [Full Text] [Related]
17. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.
Petru E; Schmähl D
Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170
[TBL] [Abstract][Full Text] [Related]
18. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Noguchi S; Yamamoto H; Inaii H; Koyama H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
[TBL] [Abstract][Full Text] [Related]
19. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
20. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
